"We're doing the bold thing" by going for phase III superiority [rather than non-inferiority] vs. standard of care with an antibiotic in Clostridium difficile (C. diff) infection, Summit Therapeutics plc CEO Glyn Edwards told BioWorld Today, and it's going to cost about $100 million.